The medical records of 38 pre-adolescent (aged ≤ 10 years) and 43 adolescent (aged 11 -15 years) patients with primary osteosarcoma treated using the same protocol were reviewed in order to determine whether the clinical features and prognosis differed between these two groups. Gender, tumour location, tumour size, serum levels of alkaline phosphatase and lactic dehydrogenase before treatment, and chemotherapy-induced tumour necrosis were recorded, together with survival data. These parameters were compared in the two groups, and their prognostic significance was evaluated in the pre-adolescent patients. There were no statistically significant differences in the clinical parameters between preadolescent and adolescent patients. Only a poor level of chemotherapy-induced tumour necrosis was significantly associated with a poor prognosis in preadolescent patients. This study indicates that osteosarcoma behaviour is similar in pre-adolescent and adolescent patients, and there appears to be little justification for adopting different therapies in these two groups.
Introduction
Osteosarcoma is the most common childhood malignancy of bone. 1 Its incidence peaks in early to mid adolescence and the tumour is relatively rare in pre-adolescent children. It is well known that age is a significant prognostic factor in some types of paediatric cancer, such as acute lymphocytic leukaemia and neuroblastoma. 2, 3 Thus, the occurrence of osteosarcoma in preadolescence could have prognostic significance, but the reported data on the clinical outcome of pre-adolescent osteosarcoma are inconsistent. Some authors have found that survival in pre-adolescent patients is no worse than that in adolescents, 4 -7 whilst others have reported that the prognosis of pre-adolescent patients is poorer than that of adolescents. 8, 9 The aim of this study was to determine whether osteosarcoma in preadolescent patients differs in its biology and has a poorer prognosis compared with osteosarcoma in adolescent patients. Previously established prognostic factors were examined in order to compare the clinical importance of these factors in the two different patient groups; factors included gender, tumour location, tumour size, serum alkaline phosphatase 10 -13 and serum lactic dehydrogenase levels before treatment, and chemotherapy-induced tumour necrosis. 4, 12, 14, 15 Patients and methods
PATIENTS
The medical records of paediatric patients with osteosarcoma diagnosed and treated at our hospital between 1992 and 2004 were reviewed. Patients were classified into two groups: pre-adolescents (aged 10 years or younger) and adolescents (aged 11 -15 years). All patients underwent the same treatment protocol.
The prognostic factors of gender, tumour location, tumour size, serum alkaline phosphatase and serum lactic dehydrogenase levels before treatment and chemotherapy-induced tumour necrosis, together with survival data, were recorded for all the patients. Microscopic slides of biopsy specimens were reviewed by two pathologists to confirm the pathological diagnosis. Ethical approval was not required for this study.
CHEMOTHERAPY AND SURGERY
Neo-adjuvant and adjuvant chemotherapy was given according to Rosen's T-10 regimen. 16 Pre-operative chemotherapy consisted of weekly administration of highdose methotrexate (12 g/m 2 ) for 2 consecutive weeks, followed by cisplatin (100 mg/m 2 for 1 day) and doxorubicin (30 mg/m 2 for 2 days). Two courses of this three-drug combination chemotherapy were followed by definitive surgery.
Chemotherapy following surgery was stratified according to the tumour necrosis rate; pathological assessment of the effect of chemotherapy is now universally accepted as an integral element of the multi-modal approach. The histological response in the resected tumours was categorized as described by Rosen et al. 12 The chemotherapeutic agents given to patients whose tumour exhibited ≥ 90% necrosis (good responders) were the same as those they had been given before surgery. The adjuvant chemotherapy regimen for patients with tumour necrosis of < 90% (poor responders) consisted of cisplatin, doxorubicin, ifosfamide and bleomycin. Ifosfamide (14 g/m 2 ) was infused continuously for 7 days with bleomycin (30 mg/m 2 ) instead of cisplatin and doxorubicin.
FOLLOW-UP
Patients were followed-up monthly at our out-patient clinic by radiography of the chest and the affected bones for 2 years from diagnosis, at intervals of 2 months from the third year, then at longer intervals for 2 years; from the fifth year radiographs were obtained annually. Computed tomography scans of the chest and radionuclide bone scans were performed every 3 months for 2 years, and then at 6-month intervals during the third year.
STATISTICAL ANALYSIS
Event-free survival was defined as the time for which patients were determined to be free of disease (absence of pulmonary or other metastases and of local recurrence) after the primary tumour had been extirpated. Calculation of the overall survival rate included all patients who had metastases and who had been treated for them, and was calculated using the Kaplan-Meier survival curve.
The impact of the various prognostic factors was assessed using the log-rank test in pre-adolescent patients. Differences between the pre-adolescent and adolescent groups were assessed using the χ 2 test. P-values < 0.05 were considered to be statistically significant.
Results
A total of 81 paediatric patients with osteosarcoma were included in the study, 38 patients were pre-adolescents and Osteosarcoma in pre-adolescent patients 43 patients were adolescents. The median follow-up duration was 40 months. One of the 81 patients did not receive chemotherapy because this patient's general condition was not good enough to accept the treatment. Among the 80 patients who received chemotherapy, one patient was not given neo-adjuvant chemotherapy because this patient needed surgery for a pathological fracture before neo-adjuvant chemotherapy.
COMPARISONS BETWEEN PRE-ADOLESCENT AND ADOLESCENT PATIENTS
Patient characteristics and clinical parameters in the pre-adolescent and adolescent groups are shown in Table 1 . No significant clinical differences were found between the two groups, although the rate of limb salvage was slightly higher in adolescent patients. The 5-year event-free survival was 60% in pre-adolescents and 55% in adolescents (Fig. 1) ; this difference was not statistically significant. Overall 5-year survival was 64% and 59% in pre-adolescents and adolescents, respectively.
PROGNOSTIC VARIABLES IN PRE-ADOLESCENT PATIENTS
The median age of the pre-adolescent patients was 8.3 years. There were more males than females, but this difference was not statistically significant. Of the 38 pre-adolescent patients, 33 had stage IIB disease according to the Musculoskeletal Tumor Society system 17 (high grade with an extra compartment). Only a poor level of chemotherapy-induced tumour necrosis indicated a significantly poor prognosis in pre-adolescent patients (P = 0.0125); the other variables measured had no prognostic significance (Table 1) .
Event-free survival was 54.5% and overall survival was 53.7% at 152 months in stage IIB patients.
Ten patients were aged < 7 years. They had a median follow-up duration of 19 months and 20% achieved a good histological response, which was a slightly lower rate than in the older preadolescents. Two of the 10 patients required amputation for progressive disease and neurovascular bundle involvement, respectively. Thus, the frequency of amputation seemed to be higher in these younger patients, but the numbers involved were too small for us to draw a statistical inference. 
Discussion
With the introduction of chemotherapy, especially with the development of modern multi-modality treatment protocols, the survival rate of patients with osteosarcoma improved from 20% to more than 60%. 7 However, despite the development of multimodality treatments, the overall survival of patients with osteosarcoma remains limited to around 60 -70% and there has been no improvement over the past 20 years. Most authors accept the importance of intensifying systemic chemotherapy in order to improve the survival of these patients, but small increases in chemotherapeutic intensity have always been coupled with additive side-effects, such as cardiotoxicity and nephrotoxicity. 9, 15, 16 The identification of individuals with a poor prognosis has considerable merit in terms of determining the intensity of chemotherapy, though the assessment of individual risk should be based on reliable prognostic factors.
It is well known that age is a significant prognostic factor in some types of paediatric cancer, such as acute lymphocytic leukaemia and neuroblastoma; therefore, pre-adolescence could be a possible prognostic risk factor in osteosarcoma. Some data relating to the clinical outcomes of very young osteosarcoma patients have been published, 18 but cure rates in pre-adolescents with osteosarcoma vary. Some authors have reported that the survival of pre-adolescent patients is no worse than that of adolescent patients. Kozakewich et al. 19 reported that young children resembled adolescents in the pathological features and behaviour of osteosarcoma, whereas Scranton et al. 20 reported that the prognosis of young patients was poorer than that of older patients, suggesting that more intensive and aggressive treatment is needed in younger patients. In the present study, pre-adolescent patients had a 5-year survival of 64% and an event-free survival of 60%, which were similar to the results in adolescent patients (59% and 55%, respectively) treated with the same protocol.
The present institutional review of osteosarcoma in pre-adolescent patients did not reveal any significant prognostic factors among the following variables: gender, tumour location, tumour size, and initial serum alkaline phosphatase or serum lactic dehydrogenase levels. The only statistically significant variable identified in terms of overall survival was chemotherapy-induced tumour necrosis (P = 0.0125). This is consistent with previous reports. 21 The present study indicates that osteosarcoma behaviour is similar in preadolescent and adolescent osteosarcoma patients. This is supported by previous reports in the literature. 22 In conclusion, there does not appear to be any reason to use different therapies to treat pre-adolescent and adolescent osteosarcoma patients.
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